ISRCTN28490479
Completed
Not Applicable
tritional Support in Patients with newly diagnosed oEsophageal Cancer: a randomised, double blind, controlled clinical trial
Danone Research (Netherlands)0 sites67 target enrollmentJune 10, 2011
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Danone Research (Netherlands)
- Enrollment
- 67
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Newly diagnosed with carcinoma of the oesophagus or gastro\-oesophageal junction (Siewert\-Stein classification type I \- III)
- •2\. Age more than or equal to 18 years
- •3\. Written informed consent
- •Reference group (were included for baseline comparisons, no intervention in these subjects):
- •1\. Age and sex\-matched with the Dutch oesophagus cancer population
- •2\. Written informed consent
- •3\. Body mass index (BMI) 18\.5\-30 kg/m2
Exclusion Criteria
- •1\. Life expectancy \< 3 months
- •2\. Planned start of cancer treatment within 3 weeks
- •3\. Eastern Cooperative Oncology Group (ECOG) performance status \> 2
- •4\. Any oesophagus related surgery after diagnosis before inclusion
- •5\. Chemo\- and/or radiotherapy in the past 5 years
- •6\. Altered immune function \[e.g. caused by major active infection, autoimmune disease, active allergy, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, or by use of medication such as immunosuppressive drugs, immunomodulators, or corticosteroids (unless not considered to be systemically available)]
- •7\. Dysphagia score of 4 using the dysphagia scoring system
- •8\. Dependence on tube feed or parenteral nutrition in the last 4 weeks
- •9\. Use of fish oil containing supplements during the last 4 weeks
- •10\. Intolerance or allergy to dairy, fish, or other ingredients of the study products
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomidePhase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomideMedDRA version: 9.1Level: LLTClassification code 10018336Term: GlioblastomaMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-001078-34-NLMaastro Clinic57
Recruiting
Not Applicable
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with concomitant temozolomide and radiotherapy.glioblastoma10029211NL-OMON32210Academisch Ziekenhuis Maastricht58
Active, not recruiting
Phase 1
Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaMedDRA version: 20.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10003939Term: B-lymphoblastic lymphoma (Kiel Classification)System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-003430-13-IEChildren's Oncology Group9,483
Active, not recruiting
Phase 1
DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012ewly diagnosed retinoblastoma patientsMedDRA version: 14.1Level: PTClassification code 10038916Term: RetinoblastomaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-006109-85-ITA.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA120
Not yet recruiting
Not Applicable
Should a patient with a clinically suspected scaphoid fracture be treated with a cast?clinical suspected scaphoid fracture. Klinische verdenking scaphoid fractuurNL-OMON20183Erasmus MC180